Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom's macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics Well capitalized with cash and marketable securities of $457.5 million SAN ...